MD Anderson and Sangamo are overcoming the need for autologous cells in CAR-expressing T cell-based immunotherapies. The group has used gene-modifying tools to mask donor-derived T cells from immune surveillance machinery in the recipient and is planning clinical trials with such cells targeting CD19.